Hofbauer SL, et al. - Researchers assessed the cancer detection rates (CDR) of Prostate Imaging Reporting and Data System (PI-RADSv2) in a large prospective cohort. They included men with primary or prior negative biopsies who has undergone MRI/ultrasound fusion-guided targeted biopsy (TB) and 10-core systematic prostate biopsy (SB) between September 2015 and May 2017. A significant association of PI-RADSv2 with the presence of clinically significant prostate cancer (csPCa) was seen. Considerably higher CDR for PI-RADSv2 category 4 lesions was noted than previously reported. If only TB was performed, 16%clinically significant tumors would have been missed.